SUBSCRIBE
SUBSCRIBE

Panbela Therapeutics Inc.

IN THE PRESS
Business
Panbela Provides Business Update and Reports Q1 2022 Financial Results
May 12, 2022
 · 
12 min read
BioMidwest
Panbela to Host Virtual R&D Day - Apr 27, 2022
April 27, 2022
 · 
5 min read
BioMidwest
Panbela Announces Poster Presentation at American Association for Cancer Research:The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer
April 12, 2022
 · 
8 min read
Business
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results
March 24, 2022
 · 
14 min read
BioMidwest
Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28, 2022, at 12:00 pm ET
March 23, 2022
 · 
6 min read
BioMidwest
Panbela to Participate in the 34th Annual Roth Conference
March 10, 2022
 · 
5 min read
Business
Panbela Schedules Conference Call on March 24, 2022, to Report 2021 Fourth Quarter Financial Results
March 8, 2022
 · 
5 min read
BioMidwest
Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)
March 7, 2022
 · 
5 min read
Deals
Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.
February 22, 2022
 · 
12 min read
Drug Development
Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
January 26, 2022
 · 
5 min read
Load More
JOBS